

Nagrestipen

Cat. No.:	HY-P3627
CAS No.:	166089-33-4
Molecular Formula:	C ₃₃₈ H ₅₁₆ N ₈₈ O ₁₀₈ S ₄
Molecular Weight:	7668.48
Sequence Shortening:	SLAADTPTACCFSYTSRQIPQNFIAAYFETSSQCSKPGVIFLTKRSRQVCADPSEEWVQKYVSDL ELSA (Disulfide bridge:Cys10-Cys34;Cys11-Cys50)
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Nagrestipen, a human macrophage inflammatory protein-1 alpha (MIP-1α) variant, also known as ECI 301. Nagrestipen has antitumor activity and can be used in therapeutic trials to study cancer, tumors, metastases, radiation oncology, and tumor metastasis ^[1] .								
In Vivo	<p>Nagrestipen (ECI 301) (i.v; 2 μg; daily for 5 days) significantly inhibits tumor growth at 6 Gy local irradiation of tumor sites and enhances the distant septal effect of radiation in male BALB/c mice^[1].</p> <p>Nagrestipen (ECI 301) (i.v; 0.08, 0.4, 2 μg; day 1,8,15) can inhibit tumor growth in a dose-dependent manner at both irradiated and unirradiated sites of female C57BL/6 with LLC cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male BALB/c mice with Colon26 cells and MethA cells^[1]</td> </tr> <tr> <td>Dosage:</td> <td>2 μg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection; daily for 5 days</td> </tr> <tr> <td>Result:</td> <td>Significantly inhibited tumor size without significant toxicity. Stopped tumor growth in the colon not only at the irradiated site but also at the unirradiated.</td> </tr> </table>	Animal Model:	Male BALB/c mice with Colon26 cells and MethA cells ^[1]	Dosage:	2 μg	Administration:	Intravenous injection; daily for 5 days	Result:	Significantly inhibited tumor size without significant toxicity. Stopped tumor growth in the colon not only at the irradiated site but also at the unirradiated.
Animal Model:	Male BALB/c mice with Colon26 cells and MethA cells ^[1]								
Dosage:	2 μg								
Administration:	Intravenous injection; daily for 5 days								
Result:	Significantly inhibited tumor size without significant toxicity. Stopped tumor growth in the colon not only at the irradiated site but also at the unirradiated.								

REFERENCES

[1]. Kenshiro Shiraishi, et al. Enhancement of antitumor radiation efficacy and consistent induction of the abscopal effect in mice by ECI301, an active variant of macrophage inflammatory protein-1alpha. Clin Cancer Res. 2008 Feb 15;14(4):1159-66.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA